- cafead Mar 01, 2021 at 11:32: AM
via After announcing a successful primary endpoint in November, AstraZeneca and Amgen presented the full data on their severe asthma antibody candidate on Friday.
The Phase III double-blinded trial, NAVIGATOR, showed the duo’s potentially first-in-class medicine tezepelumab to significantly reduce the annual asthma exacerbation rate (AAER) in severe, uncontrolled asthma patients.
article source
The Phase III double-blinded trial, NAVIGATOR, showed the duo’s potentially first-in-class medicine tezepelumab to significantly reduce the annual asthma exacerbation rate (AAER) in severe, uncontrolled asthma patients.
article source